UA targeting rhabdomyosarcoma, a rare pediatric cancer with few treatment options
Rhabdomyosarcoma (RMS) is a rare cancer of the skeletal muscle that primarily affects pediatric patients. After diagnosis, about 3 out of 4 patients are cured with standard treatment. Survival rates drop to 17 percent if the disease comes back (recurs) and to 30 percent if it spreads (metastasizes).